Isogenica licenses CIS display tech to Aro Biotherapeutics
The agreement will serve to leverage each companies' strengths in recombinant protein technologies and biopharmaceutical development
Isogenica has announced that it has signed a new licensing agreement with Aro Biotherapeutics company (Aro) of Philadelphia, US that will leverage each companies’ strengths in recombinant protein technologies and biopharmaceutical development.
Isogenica designs and constructs highly diverse synthetic antibody libraries for use in novel in vitro polypeptide display systems.
Aro is focused on discovery and development of Centyrins, a protein drug platform designed to uniquely address unmet needs through targeted delivery of a variety of drug payloads to specific cells or tissues.
Isogenica has granted a licence to Aro to utilise its proprietary in vitro CIS Display technology, for the discovery, development and commercialisation of therapeutic products derived from Centyrin libraries generated using this technology.
Aro will use the Isogenica technology to advance its internally developed Centyrin drug pipeline.
Under the terms of the agreement, Isogenica will receive an upfront fee and annual licence payments. If therapeutic products are advanced into development, Isogenica is entitled to additional milestone payments. As part of the agreement, Isogenica will undertake Centyrin discovery services at its site on targets nominated by Aro.
Adam Collier, Isogenica’s Director of Commercial Development commented: “Isogenica continues to attract leading-edge partners, giving them access to our novel CIS Display technology and supporting them in advancing their own discovery programmes. Aro is an exciting new company with a unique technology and we look forward to our partnership with them.”
